智通财经APP获悉,周一,肥胖症药物研发初创公司Metsera(MTSR.US)开盘暴涨超60%,创历史新高,报53.47美元。消息面上,辉瑞(PFE.US)同意以约49亿美元的企业价值收购Metsera,此举旨在强化其研发管线。这家美国制药商在周一的声明中表示,将以每股47.50美元的现金收购Metsera,若达成三项特定监管里程碑,还将额外支付每股最高22.50美元。该交易较Metsera上周五收盘价溢价43%。
智通财经APP获悉,周一,肥胖症药物研发初创公司Metsera(MTSR.US)开盘暴涨超60%,创历史新高,报53.47美元。消息面上,辉瑞(PFE.US)同意以约49亿美元的企业价值收购Metsera,此举旨在强化其研发管线。这家美国制药商在周一的声明中表示,将以每股47.50美元的现金收购Metsera,若达成三项特定监管里程碑,还将额外支付每股最高22.50美元。该交易较Metsera上周五收盘价溢价43%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.